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Use of a Genetic Variant Related to Circulating 
FXa (Activated Factor X) Levels to Proxy the 
Effect of FXa Inhibition on Cardiovascular 
Outcomes
Dipender Gill , BMBCh, PhD; Stephen Burgess, PhD
Coagulation FX (factor X) is a serine protease that catalyzes the formation of fibrin clots. Although this maintains hemostasis, it can also result in pathologi-
cal thrombi and emboli.1,2 FXa (activated FX) inhibitors 
are efficacious for preventing deep venous thrombosis, 
pulmonary embolism,1 and cardioembolic stroke related 
to nonvalvular atrial fibrillation.2 However, the efficacy of 
FXa inhibitors for other forms of cardiovascular disease 
is not known.
Genetic variants related to circulating levels of a coag-
ulation factor can be used as instrumental variables in 
Mendelian randomization analyses to study the effects of 
drugs that inhibit that coagulation factor.3 The aim of this 
work was to employ a genetic instrument for circulating 
FXa levels in an exploratory investigation into the effects 
of varying FXa levels on cardiovascular outcomes.
As the instrument for circulating FXa levels, we used 
the rs61753266 variant in the F10 gene that has been 
associated with plasma FXa levels at P=8×10-15 in a 
study of 3301 European-ancestry individuals.4 Although 
the rs547138 variant in the F10 gene was associated 
with plasma FXa levels at P=6×10-22 in the same study, 
it was also associated with Protein Z–dependent pro-
tease inhibitor at P=5×10-4 4. Given the role of Protein 
Z–dependent protease inhibitor in inhibiting FXa, this 
likely represents a pleiotropic association that could 
bias Mendelian randomization analyses investigating the 
effect of FXa, and therefore this variant was not included. 
The rs61753266 variant we used had a weaker asso-
ciation with circulating Protein Z–dependent protease 
inhibitor (P=0.05).
We used the UK Biobank to perform analyses, con-
sidering the outcomes of coronary artery disease (CAD), 
peripheral artery disease, ischemic stroke, intracere-
bral hemorrhage, subarachnoid hemorrhage, deep vein 
thrombosis, and pulmonary embolism. Genetic associa-
tion estimates for these outcomes were obtained from 
367 570 unrelated European-ancestry participants. 
Cases were defined based on International Classification 
of Diseases, Ninth and Tenth Revisions, Office of Popu-
lation Censuses and Surveys Classification of Surgical 
Operations and Procedures (fourth revision), and par-
ticipant self-reported data (Table). Only incident cases 
recorded until October 11, 2019 were considered. Rel-
evant ethical approval for the UK Biobank study was 
obtained from the North West Multicentre Research 
Ethics Committee, and all participants provided informed 
consent. UK Biobank data are available on request (see 
the Acknowledgments section). The statistical code used 
is available from the corresponding author upon reason-
able request.
Odds of each outcome per FXa decreasing allele of 
rs61753266 (frequency 0.3%) are detailed in the Table. 
Consistent with existing randomized-controlled trial data, 
the genetic instrument for lower FXa levels was associ-
ated with reduced deep vein thrombosis and pulmonary 
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embolism risk.1 This instrument is also associated with 
higher subarachnoid hemorrhage risk, in keeping with 
the increased bleeding risk associated with FXa inhibi-
tors. These results, therefore, serve as a form of positive 
control, supporting the validity of the variant as an instru-
ment for FXa inhibition. There was some suggestion that 
the genetic instrument for lower FXa levels may be asso-
ciated with a reduced risk of ischemic stroke and periph-
eral artery disease, although the 95% CIs were broad. 
Inhibitors of FXa are known to be effective for reducing 
the risk of stroke related to nonvalvular atrial fibrillation.2 
The point estimates for the associations of the FXa low-
ering variant with CAD and intracerebral hemorrhage risk 
were close to the null.
This work represents an efficient way to explore the 
potential clinical applications of FXa inhibitors. The use 
of a genetic instrument for FXa levels helps overcome 
environmental confounding and reverse causation bias 
to allow causal inferences to be drawn. However, the 
approach also has limitations. Although the location of 
the variant we employ at the F10 locus and its associa-
tion with plasma FXa levels both support its validity as 
an instrument for FXa levels,4 we cannot exclude the 
possibility that it affects risk of the considered outcomes 
through pathways independent of FXa levels, to bias the 
results of our analysis. Furthermore, as apparent from 
the confidence intervals of the results, our study had 
limited statistical power. Given the previously described 
association between our instrument for circulating FXa 
levels and CAD,5 and the role of FXa in inflammation, 
vascular remodeling, and fibrosis, our null finding for this 
outcome should be interpreted with caution. The discrep-
ancy may, in part, be attributable to the criteria used to 
diagnose CAD—although Paraboschi et al5 considered 
angiographically confirmed cases and controls with no 
angiographic evidence of coronary atherosclerosis, our 
current study used International Classification of Diseases 
and Office of Population Censuses and Surveys codes, 
and self-report for case ascertainment (Table), with non-
cases considered as controls.
In conclusion, the findings of this Mendelian random-
ization study are consistent with the results of clinical trials 
in supporting an effect of FXa inhibition on reducing risk 
of venous thromboembolism and increasing risk of sub-
arachnoid hemorrhage. The results did not support that 
FXa inhibition is associated with reduced CAD risk in a 
general population. Although further study is required to 
investigate the discrepancy with previous work,5 this infor-
mation may be used to help prioritize future clinical trials.
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I25.8, I25.9 (26,730 cases 
from HES; 2449 cases 
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K43.‡, K44.‡, K45.‡, 
K46.‡, K49.‡, K50.1, 
K50.2, K50.4, K75.‡ 
(12,266 cases)
Noncancer illness code 
(20002), Surgical operation 
code (20004), Health 
condition diagnosed by doctor 










(2778 cases from HES; 
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(20002; 688 cases)
0.89 (0.57–1.38)
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I26.‡ (3905 cases from 
HES; 488 cases from 
death certificates)
 Noncancer illness code 
(20002), Health condition 
diagnosed by doctor (6152; 
3209 cases)
0.45 (0.29–0.71)
FXa indicates activated factor X; HES, hospital episode statistics; ICD, International Classification of Diseases; and OPCS, Office of Population Censuses and Surveys.
*ICD-10 diagnoses were identified through both HES and death certificates (UK Biobank fields 40001 and 40002).
†Diagnoses made by a doctor (UK Biobank fields 6150 and 6152) and Medication for health condition (6177) were self-reported by participants by touchscreen 
entry; noncancer illness code (20002) and surgical operation code (20004) were self-reported by participants by interview with a nurse.
‡Indicates that all subcodes are included.
